With its technology, the company hopes to connect more cancer patients being treated in community-based practices to beneficial clinical trials based on genomic biomarkers.
The firm's Guardant360 assay will be used first to test patients for ERBB2 mutations, then guide patients to a variety of treatment arms.
The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.
A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.
Nohla will use Karius' NGS plasma test for pathogen detection in a randomized trial evaluating Nohla's lead product, a cellular therapy called NLA101.
BMS amended an ongoing Phase III study of Opdivo and Yervoy to evaluate outcomes based on tumor mutational burden using Foundation Medicine's NGS companion diagnostic.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
Foundation Medicine will provide genomic profiling for the EORTC's Screening Patients for Efficient Clinical Trial Access program.
With fewer rules, doctors in China are moving ahead with CRISPR clinical trials, the Wall Street Journal reports.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.